Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| NKTR | 8-K | bullish | 6/10 | Nektar Therapeutics won a $90 million jury verdict against Eli Lilly for breach of the implied covenant of good faith an | Sep 25, 2026 |
| LEGN | 6-K | bullish | 5/10 | Legend Biotech announced five-year follow-up data from CARTITUDE-2 Cohort A showing that 50% of RRMM patients remained p | Sep 25, 2026 |
| CCCC | PRESS-RELEASE | neutral | 4/10 | C4 Therapeutics presented biomarker data at IMS 2026 showing cemsidomide activates T cells and prevents exhaustion in RR | Sep 25, 2026 |
| LEGN | PRESS-RELEASE | bullish | 5/10 | Legend Biotech presented five-year follow-up data from CARTITUDE-2 Cohort A at IMS 2026, showing 50% of patients remaine | Sep 25, 2026 |
| ADXN | 6-K | neutral | 4/10 | Addex Therapeutics regained full global rights to its GABAB PAM portfolio from Indivior after Indivior rationalized R&D | Sep 25, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a routine 6-K announcing the date of its 2026 Annual General Meeting (November 20, 2026) and | Sep 25, 2026 |
| LABT | EFFECT | bullish | 6/10 | The SEC declared effective a registration statement (File No. 333-299027) for Lakewood-Amedex Biotherapeutics Inc. on Se | Sep 25, 2026 |
| ADRX | EFFECT | bullish | 8/10 | The SEC declared effective ADARx Pharmaceuticals' S-1 registration statement for its initial public offering of 21,875,0 | Sep 25, 2026 |
| SNTI | EFFECT | bearish | 7/10 | The SEC declared effective Senti Biosciences' shelf registration statement on Form S-3 (File No. 333-296917) on Septembe | Sep 25, 2026 |
| MLYS | CLUSTER | bearish | 5/10 | Three insiders at Mineralys Therapeutics sold a total of $3.30M in stock over a one-week window, led by director Brian T | Sep 24, 2026 |
| VKTX | 424B5 | bearish | 5/10 | Viking Therapeutics is issuing $225M of 2.00% convertible senior notes due 2032 (plus a $33.75M over-allotment option), | Sep 24, 2026 |
| VKTX | 424B5 | bearish | 6/10 | Viking Therapeutics is conducting a dilutive follow-on offering of 7,857,143 shares at $35.00 per share, raising approxi | Sep 24, 2026 |
| MGTX | 3 | neutral | 2/10 | Alan Sebulsky filed a Form 3 initial statement of beneficial ownership, reporting 34,500 ordinary shares held indirectly | Sep 24, 2026 |
| JUNS | S-3 | bearish | 5/10 | Jupiter Neurosciences filed an S-3 registration statement to register 132,867 shares of common stock for resale by Pharm | Sep 24, 2026 |
| REGN | GOVT-CONTRACT | bullish | 5/10 | Regeneron Pharmaceuticals received a $277.8 million government contract modification from HHS for INMAZEB Ebola therapeu | Sep 24, 2026 |
| ADRX | PRESS-RELEASE | bullish | 7/10 | ADARx Pharmaceuticals priced its upsized IPO of 26.25M shares at $17.00/share, with gross proceeds of ~$446.3M, plus a c | Sep 24, 2026 |
| ADRX | 3 | neutral | 1/10 | Simeon George, managing member of SR One Capital Management, filed an initial Statement of Beneficial Ownership (Form 3) | Sep 24, 2026 |
| ADRX | 3 | neutral | 3/10 | OrbiMed Advisors LLC and affiliated entities filed a Form 3 initial statement of beneficial ownership for ADARx Pharmace | Sep 24, 2026 |
| ALMR | PRESS-RELEASE | bullish | 5/10 | Alamar Biosciences announced a publication in The Lancet Neurology of a longitudinal cohort study using its NULISAseq CN | Sep 24, 2026 |
| ADRX | 3 | neutral | 2/10 | Mary Tagliaferri, M.D. filed a Form 3 initial statement of beneficial ownership with ADARx Pharmaceuticals, reporting st | Sep 24, 2026 |
| ADRX | 3 | neutral | 2/10 | Erez Chimovits, a director of ADARx Pharmaceuticals, filed a Form 3 initial statement of beneficial ownership, reporting | Sep 24, 2026 |
| ADRX | 3 | neutral | 2/10 | Carl L. Gordon, Ph.D., CFA, a representative of OrbiMed Advisors, filed an initial Statement of Beneficial Ownership (Fo | Sep 24, 2026 |
| ADRX | 3 | neutral | 2/10 | Zhen Li, Ph.D., the President and CEO of ADARx Pharmaceuticals, filed a Form 3 initial statement of beneficial ownership | Sep 24, 2026 |
| JAGX | SC 13G/A | bearish | 5/10 | Joshua Mailman filed an amended Schedule 13G disclosing a 9.99% passive stake in Jaguar Health, Inc. as of September 12, | Sep 24, 2026 |
| RVMD | CLUSTER | bearish | 4/10 | Eight Revolution Medicines insiders sold a total of $6.07M in open-market sales over a one-week window, including the CO | Sep 24, 2026 |
| CRSP | CLUSTER | bearish | 5/10 | Two CRISPR Therapeutics insiders, Director Ali Behbahani and General Counsel James Kasinger, sold a combined $1.41M in o | Sep 24, 2026 |
| ACAD | 8-K | bullish | 6/10 | Acadia Pharmaceuticals announced Phase 3-enabling topline results from the Phase 2 portion of the RADIANT trial evaluati | Sep 24, 2026 |
| BMRA | S-3 | bearish | 5/10 | Biomerica filed an S-3 shelf registration to register 1,403,705 shares of common stock for resale by selling stockholder | Sep 24, 2026 |
| HURA | 8-K | neutral | 2/10 | TuHURA Biosciences drew an additional $650,000 under its existing $50 million revolving credit facility with Parkview Ho | Sep 24, 2026 |
| SNTI | DEFM14A | bearish | 7/10 | Senti Biosciences is seeking stockholder approval of a merger with a Celadon Partners affiliate that will result in no u | Sep 24, 2026 |